Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGI-F701 in female hair loss
NCT03351322Phase 2Completed
- Sponsor
- Energenesis Biomedical Co., Ltd.
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ENERGI-F701 in Female Pattern Hair Loss (FPHL) (2 arms), sponsored by Energenesis Biomedical Co., Ltd. Primary endpoint: The amount of hair loss at 12 weeks. Started May 2018; status: completed.
02
Drugs
ENERGI-F701
03
Conditions
Female Pattern Hair Loss (FPHL)
Beyond the preview
Go deeper on NCT03351322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351322.